Can vancomycin cause an increase in serum creatinine?

Can Vancomycin Increase Creatinine Levels?

Yes, vancomycin can cause increases in serum creatinine levels and is a recognized cause of nephrotoxicity in hospitalized patients.

Definition of Vancomycin-Induced Nephrotoxicity

According to consensus guidelines from the Infectious Diseases Society of America (IDSA), the American Society of Health-System Pharmacists (ASHP), and the Society of Infectious Diseases Pharmacists, vancomycin-induced nephrotoxicity should be diagnosed when at least 2-3 consecutive elevated serum creatinine measurements (increase of ≥0.5 mg/dL or ≥50% increase from baseline, whichever is greater) are documented after several days of vancomycin therapy in the absence of an alternative explanation 1.

The FDA drug label confirms that systemic vancomycin exposure may result in acute kidney injury (AKI), with risk increasing as serum levels/systemic exposure increase 2.

Clinical Evidence and Magnitude of Risk

The relationship between vancomycin and creatinine elevation is well-established:

• In a large multicenter study of 128,993 hospitalized patients receiving vancomycin, 51% experienced some degree of serum creatinine elevation, with 26% having increases of 1-20%, and progressively smaller percentages experiencing larger increases 3

• Among critically ill adolescents and young adults, vancomycin-associated AKI occurred in 40% of patients 4

• Even a 10% post-vancomycin creatinine increase was associated with increased mortality risk, with a graded relationship showing mortality odds ratios ranging from 1.60 to 13.66 corresponding to creatinine increases of 10% to >200% 3

Key Risk Factors for Nephrotoxicity

Multiple factors increase the risk of vancomycin-induced creatinine elevation:

Patient-related factors:

• Increasing age 5
• Higher body weight 5
• Pre-existing renal impairment 2
• Critically ill status 5

Treatment-related factors:

• Higher vancomycin doses 5
• Elevated vancomycin trough levels (particularly >31 mg/L) 4
• Longer duration of therapy 5
• Concurrent nephrotoxic medications (95% of AKI patients vs 60% of non-AKI patients) 4
• Concurrent vasopressor therapy 4
• Undergoing procedures while on vancomycin 4

Pharmacokinetic factors:

• Vancomycin AUC >650 mg×hour/L is associated with increased AKI risk. AUC <650 mg×hour/L showed decreased AKI odds ratios of 0.36 for first 24-hour AUC and 0.45 for 24-48 hour AUC 6

Important Caveats: True Nephrotoxicity vs. Pseudotoxicity

A critical distinction exists between true kidney injury and isolated effects on creatinine secretion. Recent evidence suggests that when vancomycin is combined with piperacillin-tazobactam, the observed creatinine increases may represent "pseudotoxicity" rather than true kidney damage:

• Vancomycin + piperacillin-tazobactam was associated with 8% higher creatinine increases and 34% higher creatinine-defined AKI rates 7
• However, this combination was not associated with changes in cystatin C (a biomarker unaffected by tubular secretion), blood urea nitrogen, dialysis requirement, or mortality 7
• This supports the hypothesis that some creatinine elevations may reflect inhibition of tubular creatinine secretion rather than actual kidney injury

Monitoring Recommendations

The IDSA/ASHP guidelines specify 1:

• Monitor trough serum vancomycin concentrations (not peak levels) to reduce nephrotoxicity risk, particularly for:

  • Patients receiving aggressive dosing targeting trough concentrations of 15-20 mg/L
  • Patients at risk of toxicity (concurrent nephrotoxins, pre-existing renal dysfunction)
  • Patients with unstable renal function

• Monitor renal function in all patients, especially those with underlying renal impairment, co-morbidities predisposing to renal dysfunction, or receiving concurrent nephrotoxic drugs 2

• Consider measuring cystatin C levels in addition to creatinine, particularly in patients with reduced muscle mass, older age, extended hospitalization, or ICU stay, as creatinine-based formulas may overestimate GFR in these populations 8

Clinical Implications

The guidelines acknowledge that there are limited data suggesting a direct causal relationship between specific vancomycin concentrations and toxicity, with conflicting data characterized by confounding nephrotoxic agents and inconsistent definitions 1. However, the preponderance of evidence supports that vancomycin can cause true increases in creatinine and nephrotoxicity, particularly at higher exposures and in the presence of risk factors.

AUC-guided monitoring may result in less vancomycin-associated AKI compared to trough-guided monitoring (OR 0.68), suggesting that optimizing dosing strategies can reduce nephrotoxicity risk 6.